Lifeline extended for rare metabolic disorder patients
NCT ID NCT02404896
Summary
This program provides continued access to metreleptin, a hormone replacement therapy, for patients with partial lipodystrophy who previously benefited from treatment in a clinical study. The program is for patients who showed improvement in diabetes control, triglyceride levels, or other metabolic problems while taking the medication. It allows eligible patients to continue treatment without interruption after the original study ended.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL PARTIAL LIPODYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Michigan
AVAILABLEAnn Arbor, Michigan, 48105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.